The targeting construct was designed to insert a loxP-flanked neomycin (neo) resistance cassette downstream of exon 2. The double mutation, F101C/A105G, was introduced in exon 2 and a third mutation, N153T, was introduced into exon 3. Cre-mediated recombination removed the floxed neo cassette.